Economics, equity and avoidable mortality

IF 58.7 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Nature Medicine Pub Date : 2024-10-22 DOI:10.1038/s41591-024-03303-0

Jeong-Yeon Cho, Nathorn Chaiyakunapruk

引用次数: 0

Abstract

Two new studies characterize the unequal global burden of avoidable mortality and the economic value of reducing it — providing evidence to support targeted investment in health and longevity.

Abstract Image

查看原文本刊更多论文

经济学、公平和可避免的死亡率

两项新的研究描述了可避免的死亡率在全球造成的不平等负担以及降低死亡率的经济价值，为支持对健康和长寿进行有针对性的投资提供了证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Medicine 医学-生化与分子生物学

CiteScore

100.90

自引率

0.70%

发文量

525

审稿时长

1 months

期刊介绍： Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors. Nature Medicine consider all types of clinical research, including: -Case-reports and small case series -Clinical trials, whether phase 1, 2, 3 or 4 -Observational studies -Meta-analyses -Biomarker studies -Public and global health studies Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.